A Phase 2 interventional study of Lopinavir/ritonavir and Efavirenz in HIV Infections, sponsored by Abbott. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2006-07-27.
Sponsored by Abbott · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 101 studies testing efavirenz in HIV Infections — none open to participants now, none under way, none of them phase 3. efavirenz · HIV Infections.
Among the 101 studies testing efavirenz in HIV Infections, this one is the 68th largest by enrollment of the 96 interventional ones that give a count, is one of 3 that started in 2000, is one of 22 in phase 2, and was the 31st registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →None of the 101 studies testing efavirenz in HIV Infections is open now. The open studies under HIV Infections, anywhere →
efavirenz: first FDA approval 1998 (SUSTIVA), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
101 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 24 · Phase 3 28 · Phase 4 28
First in 1997; this study’s year is marked. 3 started in 2000.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 75 across the 96 interventional studies. Of the 91 that completed or were terminated, 18 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 101 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
27 studies in HIV Infections by Abbott: none open now, none under way, none of them phase 3. Of 26 finished, 0 (0%) have results posted.
Among the 27 studies in HIV Infections by Abbott, this one is the 12th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2000, is one of 7 in phase 2, and was the 14th registered.
Abbott’s HIV Infections studies by the year they started, since 1992.
None of the studies under way reaches primary completion within a year.
Among the 101 studies testing efavirenz in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Abbott’s 27 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to see if a novel 4-drug anti-HIV combination can suppress the growth of HIV in patients infected with the virus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proportion of subjects in each group demonstrating complete suppression of viral replication at Week 144.
This study is completed, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Efavirenz · Lamivudine · Tenofovir